Introduction
The Philadelphia chromosome (Ph + ) reflects a balanced reciprocal translocation between the long arms of chromosomes 9 and 22 [t(9;22)(q34; q11.2)] involving the BCR and ABL genes, respectively. 1,2 Three breakpoint cluster regions in the BCR gene have been described so far: major(M)-minor(m)-and micro ()-BCR. [3] [4] [5] [6] These breakpoints result in BCR-ABL fusion proteins that differ in their size and transforming potential 4 ,5 the p210, p190 and p230 proteins, respectively. While the M-BCR breakpoint is the genetic hallmark of chronic myeloid leukemia (CML), 7, 8 Ph + precursor Bacute lymphoblastic leukemias are usually associated with the m-BCR and to a much lesser extent with M-BCR gene rearrangements. 9 Among precursor-B-ALL cases, t(9;22) translocation occurs in around 20-30% of adults and in р5% of children. [10] [11] [12] [13] [14] [15] [16] From the clinical point of view, Ph + precursor-B-ALL is associated with a highly aggressive disease frequently resistant to chemotheraphy and with a short survival. 14, [17] [18] [19] [20] [21] Therefore, at present, detection of BCR/ABL gene rearrangements is mandatory in precursor-B-ALL patients at diagnosis for prognostic stratification and treatment decision making. Unfortunately, a rapid screening method, displaying a high sensitivity and specificity, for identification of BCR/ABL + precursor-B-ALL cases is not currently available. Although an association between BCR/ABL gene rearrangements and a common (BII) phenotype has long been reported 22 it is well-established that reactivity for CD10 in the absence of cIg and sIg expressiona common, BII phenotype -is also present in around half of all BCR/ABL − precursor-B-ALL cases. 22, 23 Therefore, molecular and/or cytogenetic studies directed to the identification of BCR/ABL gene rearrangements should be performed in all precursor-B-ALL cases, from which only a minor proportion would be positive.
The immunophenotypic characteristics of precursor B-ALL leukemic cells have long been believed to reflect normal hematopoietic B cell precursors. However, more recent studies have shown that through the simultaneous assessment of several antigens almost all precursor-B-ALL cases display phenotypic aberrations. [23] [24] [25] [26] [27] Such phenotypic aberrations may be associated with specific genetic abnormalities, and it has been suggested that they could be used to better understand dysregulation of protein expression and at the same time they could help in identifying cases carrying specific genetic lesions such as t(12;21) [28] [29] [30] and 11q23 abnormalities. [31] [32] [33] The aim of the present study was to explore in detail the immunophenotypic characteristics of precursor B-ALL cases displaying BCR/ABL gene rearrangements in order to rapidly identify unique phenotypes associated with this translocation; patients showing such phenotypic profile should be considered as high priority cases for molecular confirmation of BCR/ABL translocation if the technique is available, or if not categorized as positive in a therapeutic decision-making process. Our results show that the combined use of the patterns of CD34, CD38 and CD13 expression among CD10-positive precursor-B ALL adult patients is highly suggestive of BCR/ABL gene rearrangements.
Materials and methods

Patients
A total of 82 consecutive patients whose bone marrow (BM) samples were referred to the laboratory of the University Hospital of Salamanca for immunophenotypic and molecular/ cytogenetic analysis were included in the present study. All patients had an unequivocal diagnosis of 'de novo' precursor B-ALL based on morphological, cytochemical and immunophenotypic criteria; 34 of the patients analyzed, 54 were males and 28 were females. In children (n = 32) mean age was 4 ± 4 years (median 3 years) while in adults (n = 50) it was 41 ± 19 years (median 36 years). All cases were studied at diagnosis.
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Immunophenotypic studies
In all cases immunophenotypic studies were performed at diagnosis on erythrocyte-lysed whole BM samples upon staining with monoclonal antibodies directly conjugated to fluorochromes. Antigen expression was analyzed on a FACSort flow cytometer (Becton Dickinson Biosciences, San Jose, CA, USA) using triple-stainings for the following combinations of fluorochrome-conjugated monoclonal antibodies (fluorescein isothiocyanate (FITC), phycoerythrin (PE) and either peridin clorophyll protein (PerCP) or the PE/cyanine 5 (Cy5) fluorochrome tandem) directed against cell surface antigens: CD4/CD8/CD3, CD7/CD5/CD3, CD19/CD34/CD45, CD10/ CD13/CD19, CD5/CD33/CD20, CD34/CD38/CD19, CD10/ CD20/CD19, CD7/CD2/CD3, CD34/CD22/CD19, Tdt/CD10/ CD19, CD7/CD34/CD38, and kappa/lambda/CD19. In addition, the expression of MPO, CD79a, IgM and CD3 was also explored at the cytoplasmic level.
Briefly, BM samples were obtained and immediately diluted in phosphate-buffered saline (PBS) containing K 3 EDTA as anticoagulant at a proportion of 1/1 (v/v). Afterwards, for surface antigenic stainings, 200 l of PBS-diluted BM samples, containing between 0.5 and 1 × 10 6 nucleated cells were placed in each tube and incubated with the appropriate combination of monoclonal antibodies for 15 min at room temperature in the dark. Once this incubation period was finished, 2 ml of FACS lysing solution (Becton Dickinson) diluted 1/10 (v/v) in distilled water were added to each tube and after vigorous vortexing another incubation for 10 min in the darkness (room temperature) was performed. Afterwards, cells were centrifuged (5 min at 540 g), washed once in 2 ml of PBS/tube (5 min at 540 g) and resuspended in 0.5 ml/tube of PBS.
For the staining of cytoplasmic antigens (MPO, CD79a and CD3) the Fix & Perm reagent from Caltag Laboratories (San Francisco, CA, USA) was used, strictly following the recommendations of the manufacturer.
The source and specificity of each monoclonal antibody reagent used in the present study was as follows: CD34 (HPCA-2-PE and My10-FITC), CD33 (leu M9-PE), CD38 (leu 17-PE), CD13 (leu M7-PE), CD7 (leu 9-FITC), CD10 (CALLA-FITC), CD5 (leu 1-FITC and leu 1-PE), CD3 (leu 4-PerCP), CD4 (leu 3-FITC), CD8 (leu 2-PE), CD19 (leu 12-FITC), CD20 (leu 16-PE), CD22 (leu 14-PE), anti-kappa-FITC and anti-lambda-PE were purchased from Becton Dickinson, CD19 (SJ25C1-PE/Cy5), MPO (H435-FITC), CD38 (HB7-PE-Cy5), polyclonal anti-IgM (PE), CD20 (HI47-PE-Cy5), and CD45 (HI30-PE/Cy5) were obtained from Caltag Laboratories, CD79a (HM57-PE) and anti-Tdt (HT-6-PE) from Dako (Glostrup, Denmark) and CD2 (SFCI3Pt2H9-T11-PE) and CD10 (J5-PE) from Beckman Coulter (Miami, FL, USA).
Isotype-matched mouse non-specific immunoglobulins and a tube stained for the CD4-FITC, CD8-PE and CD3-PerCP antigens were used as negative and positive controls, respectively.
Data acquisition was performed using the CellQuest software program (Becton Dickinson) and information on a minimum of 15 000 events/tube from the total BM cellularity was acquired. In order to make results comparable between different days, careful instrument calibration and fluorescence compensation was performed using both CALIBRITE beads (Becton Dickinson) and normal peripheral blood (PB) lymphocytes stained for CD4-FITC, CD8-PE and CD3-PE/Cy5 or PerCP as previously described. 35 For data analysis the PAINT-A-GATE PRO software (Becton Dickinson) was used. Whenever necessary, further stainings were made in a second step Leukemia in order to be able to specifically gate on leukemic cells. The following information was explored on the leukemic cells for each of the antigens analyzed: (1) presence or absence of antigen expression; (2) fluorescence intensity, as reflected by the mean fluorescence intensity (MFI) expressed in relative linear fluorescence chanels scaled from 0 to 10 000 (arbitrary units); and (3) the pattern of antigen expression (homogeneous vs heterogeneous) as reflected by the coefficient of variation (CV) of the fluorescence intensity obtained for each fluorochromeconjugated monoclonal antibody reagent. From the 82 cases included in this study 18 displayed a pro-B/BI phenotype, 60 corresponded to common BII and four were pre-B/BIII ALL. 34 
Flow cytometric DNA ploidy studies
The analysis of blast cell DNA contents was performed on erythrocyte-lysed whole BM samples after specifically staining for both the blast cells and cell DNA. For that purpose the Cycloscope LLA reagent kit (IMICO, Madrid, Spain) was used strictly following the recommendations of the manufacturer. Measurements of DNA cell contents were performed on a FACSCalibur flow cytometer, as previously described. 
PCR amplification of BCR/ABL transcripts
RNA was extracted from washed BM mononuclear cells by the guanidium thiocyanate method. 37 In vitro reverse transcription (RT) of total RNA to cDNA and RT-PCR amplification of M/m-BCR/ABL fusion transcripts were performed according to Biomed 1 guidelines. 38 RT was performed on 1 g of RNA, after heating at 70°C for 10 min, with random hexamers as reaction primer. The reaction was carried out at 42°C for 45 min in a 20 l volume containing 200 U of Superscript II (Life Technologies, Paisley, UK). Subsequently, 2 l of the RT product were used for two-step PCR analysis. 38 In all cases both M-BCR and m-BCR breakpoints were explored. The first round PCR was performed with the BCR-e1-A (m-BCR) (5′GACTGCAGCTCCAATGAGAAC3′) or BCR-b1-A (M-BCR) (5′GAAGTGTTTCAGAAGCTTCTCC3′) as 5′ primers and the ABL-a3-B (5′GTTTGGGCTTCACACCATTCC3′) as 3′ primer. For the second-round PCR, the system used was the same as the first round except that 1 l of the first PCR product was used instead of RT product and the primers in this case were BCR e1c (m-BCR) (5′CAGAACTCGCAACAGTCCTTC3′) or BCR-b2-c (M-BCR) (5′CAGATGCTGACCAACTCGTGT3′) as 5′ primers and ABL-a3-D (5′TTCCCCATTGTGATT ATAGCCTA3′) as 3′ primer. Two negative controls (one with RNA from the HL60 cell line and one without RNA) and several positive controls (one with RNA from K562, KCl 22-M-BCR and Tom-1 m-BCR cell lines were included in each experiment). The integrity of the RNA preparation was assessed by amplification of normal ABL RNA. A control PCR (shifted PCR) for confirmation or exclusion of false positive results was used according to the Biomed 1 guidelines. 38 
Leukemia
Fluorescence in situ hybridization (FISH) studies
FISH analysis for the t(9;22) was performed using the LSI-BCR/ABL dual-color probe (Vysis, Downers Grove, IL, USA), which allows the distinction between M-BCR/ABL and m-BCR/ABL gene rearrangements. The ABL probe was conjugated with Spectrum Orange and the BCR probe was labeled with Spectrum Green.
FISH analysis was performed on cells from BM samples prepared according to conventional cytogenetic techniques. Slides containing fixed cells were immersed in pepsin (0.1 mg/ml)(Sigma, St Louis, MO, USA) followed by fixation with 1% formaldehyde and dehydrated with ethanol according to previously reported techniques. [39] [40] The probes were placed on the slides and were denatured in a Hybrite (Vysis) thermocycler at 75°C for 1 min. Hybridization was then allowed to take place by incubating the slide overnight (16 h) in the thermocycler at 37°C. Once this incubation period was finished, slides were washed three times (3 × 10 min) in 50% formamide in 2 × SSC (pH 7.0) at 46°C, followed by another wash for 10 min in 2 × SSC (pH 7.0); finally, the slides were washed for 5 min in 2 × SSC containing Tween 20 (Sigma). Afterwards, slides were counterstained with 0.1 mg/ml of DAPI (Sigma), and Vectashield (Vector Laboratories, Burlingame, CA, USA) was used as antifading agent.
Fluorescence signals were evaluated using a fluorescence microscope (Olympus BX60, Hamburg, Germany) equipped with a 100× oil objective and a minimun of 200 cells/sample were analyzed including both interphase nuclei and metaphase chromosomes. For all slides measured the number of unhybridized cells in the areas assessed was Ͻ1% and only those spots with similar size, intensity and shape were counted. In normal cells, the probe signals appear as two distinct signals of each color (two green and two red). Cells with yellow spots (fusion of green and red signals) were interpreted as carrying BCR/ABL gene rearrangements. The distinction between M-BCR and m-BCR gene rearrangements was based on the number of fusions per cell: one or two, respectively. Based on interphase FISH studies performed in normal BM samples a case was considered to be M-BCR + and m-BCR + when more than 3% and 0.1% of the nuclei showed fused or juxtaposed BCR and ABL signals, respectively.
Statistical methods
For all phenotypic variables included in the present study their mean, median, standard deviation, 95% confidence interval and range were reported. Comparison between groups were performed using the Mann-Whitney U and chi-square tests for continuous and dichotomic variables, respectively; cut-off values for immunophenotypic markers were selected using receiver operating curves (ROC) as those values providing a 100% sensitivity with the greatest specificity. P values lower than 0.05 were considered to be associated with statistically significant differences (SPSS 8.0; SPSS, Chicago, IL, USA Tables 1 and 2 show the patterns of antigen expression detected on blast cells as reflected by the mean fluorescence intensity (MFI) and its degree of variability (coefficient of variation (CV) -homogeneous vs heterogeneous expression. As may be seen in these tables BCR/ABL + precursor-B-ALL patients constantly corresponded to common-ALL cases displaying an homogeneous (hm) expression for both CD10-FITC and CD34-PE; in addition, all these cases showed a dim and heterogenous CD13-PE expression together with an aberrantly low and heterogenous expression of CD38 (Tables 1, 2 and Figure 1 ). In contrast, among the BCR/ABL − cases the frequency at which these phenotypic features were observed was significantly lower (P Ͻ 0.02) ( Table 2) . No significant differences were observed for any of the other markers analyzed as shown in Table 1 . Such phenotypic differences were also noted once we restricted the comparison to the CD10 + precursor-B-ALL cases displaying a common/BII immunophenotype (Tables 1 and 2 ).
Multivariate analysis showed that once these four markers were combined, the patterns of CD34 and CD38 expression had an independent value to discriminate between BCR/ABL + and BCR/ABL − precursor B-ALL cases even if only BII cases were considered in the analysis; all cases in the former group were also CD10 +hm and CD13 +int (Table 2) . Furthermore, once a score system based on these immunophenotypic markers was applied to the precursor-B-ALL cases included in this study, all BCR/ABL + patients (100%) had a score of 4 while only 6% of the remaining BCR/ABL − cases -two children and one adult -simultaneously displayed the four markers defined here (Table 3) ; moreover, most of the BCR/ABL − cases (74%) showed an immunophenotypic score Ͻ3. Therefore, the simultaneous assessment of antigen expression for these four markers displayed both a high sensitivity (100%) and specificity (94%) for predicting BCR/ABL gene rearrangements in precursor-B-ALL cases (Table 4) .
Since it is well-established that adult BCR/ABL + cases still display a genetically heterogeneous background, an additional aim of our study was to explore whether the variability in the expression of other antigens among this subgroup Leukemia of precursor-B-ALL patients was related to the coexistence of additional genetic abnormalities. Accordingly, upon dividing the BCR/ABL + cases into two groups according to the presence or absence of DNA aneuploidy by flow cytometry, it was observed that DNA aneuploid BCR/ABL + cases (n = 4) displayed a higher expression (MFI values) of the CD10, CD19, CD38 and CD45 antigens as compared to the DNA diploid BCR/ABL + patients (n = 8); in addition, CD10 and CD38 showed a more homogeneous pattern of expression among DNA aneuploid BCR/ABL + cases (P = 0.01) (Figures 1 and 2 ). Interestingly, among BCR/ABL + cases the intensity of CD19 expression (MFI Ͼ100) alone was able to clearly discriminate 
Figure 1
Representative dot plots of CD10, CD34, CD38, CD13, CD19, CD45 expression in normal bone marrow (BM) (panels a to d), as well as in two BCR/ABL + (panels e to l) and in two BCR/ABL − cases (panels m to t). Panels e to h and m to p correspond to DNA diploid cases while panels i to l and q to t correspond to DNA aneuploid patients. In all panels only BM B cells are displayed. In the dot plots corresponding to normal BM (panels a to d) CD19
+ B cell precursors are painted in red; in dot plots e to t red dots correspond to B cell ALL leukemic blasts. The criteria used for definition of sensitivity, specificity and efficacy are described in Methods.
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Figure 2
Immunophenotypic differences between DNA diploid (n = 8) and DNA aneuploid (n = 4) BCR/ABL + precursor-B-ALL cases: median, standard deviation and 95% confidence interval of the distribution of the mean fluorescence intensity (MFI) of the most relevant immunophenotypic markers analyzed in the present study according to the DNA ploidy status. FITC, fluorescein isothiocyanate; PE, phycoerythrin; PE/Cy5, phycoerythrin/cyanine5.
Leukemia between the DNA diploid and the DNA aneuploid cases.
Discussion
Precursor-B-acute lymphoblastic leukemia is believed to derive from the clonal expansion and accumulation of B cell precursors which have lost their ability to completely undergo differentation. 41 Such dysregulation of cell proliferation and blockade of B-lineage maturation is probably due to the sequential accumulation of underlying genetic abnormalities, of which a large number have been identified to date. 42 Among the specific chromosome translocations identified and causally linked to leukemogenesis, BCR/ABL gene rearrangements represent one of the best characterized. 2, 43 Previous reports have shown that among precursor-B-ALL patients, this translocation is present in around 20-30% of adult cases while it is rarely detected in children, [10] [11] [12] [13] [14] [15] [16] as found in the present study.
From the functional point of view, the BCR/ABL fusion proteins are associated with an increased tyrosine-kinase activity. 44, 45 At the intracellular level, this translates into a dysregulation of transcription factors leading to abnormal patterns of protein expression. 44, 46, 47 Among the different protein cell compartments, the cytoplasmic membrane is particularly relevant, its proteins representing the interface between a particular cell and its environment. Such a relationship is crucial and impacts on the behavior of both normal and neoplastic cells. Accordingly, it might be expected that specific genetic aberrations would be translated not only into an abnormal pattern of intracellular protein expression but also into altered surface antigen expression. This would translate into the socalled 'phenotypic aberrations' (ie asynchronous antigen expression, cross-lineage antigen expression and antigen under-or overexpression, among others) which have been well-characterized in acute leukemias. [24] [25] [26] [27] Therefore, it would be expected that BCR/ABL translocation is associated with unique patterns of surface antigen expression in a similar way to what has been previously described among precursor-B-ALL for the TEL/AML1 [28] [29] [30] and 11q23 gene rearrangements. [31] [32] [33] In the present study, we clearly show that precursor-B-ALL cases carrying BCR/ABL gene rearrangements display unique phenotypic features. Accordingly, we have observed that all BCR/ABL + adult patients, including both cases with M-BCR and m-BCR breakpoint gene rearrangements, showed a homogeneous expression of the CD34 (CD34 ++hm ) and CD10 (CD10 +hm ) antigens together with a low and relatively heterogeneous expression of CD38 (CD38 50 In spite of the relatively high sensitivity displayed by some of these markers to identify BCR/ABL + ALL cases, further studies have shown that their expression is not specific of ALL patients with BCR/ABL gene rearrangements. 30, 51, 52 Interestingly, our results based on the overall phenotypic profile of blast cells, illustrate the importance of quantitative flow cytometric assessment of antigen expression, which takes into account the mean fluorescence intensity and the reactivity pattern (homogeneous vs heterogeneous) for each antigen instead of just the presence or absence of particular anti-gens (based on arbitrary cut-off values for positivity). These differences in the methodological approach would contribute in explaining both the high sensitivity and specificity of immunophenotype to identify BCR/ABL gene rearrangements among precursor-B-ALL patients found in the present study.
Moreover, our findings provide new insights into the biology of BCR/ABL + leukemic cells in adult precursor-B-ALL. Accordingly, from these unique phenotypic patterns, the abnormally low and heterogeneous reactivity for CD38 and the reactivity for CD13 represent two well-characterized antigenic aberrations. 27, 53 The expression of both markers have been shown to be finely regulated during normal hematopoiesis, including the differentiation process towards the B cell lineage. 27, [54] [55] [56] [57] [58] However, the physiological role of both antigens at the early stages of B cell maturation still remain to be elucidated. [54] [55] [56] [57] 59 Interestingly, the absence or low CD38 expression as well as the reactivity for CD13 have been reported as features of early immature CD34
+ hematopoietic progenitor and precursor cells while the commitment of these cells into the B-lymphoid lineage is associated with a marked increase in CD38 expression and down-regulation of CD13. 49, [50] [51] [52] 54 In this sense, both features apparently appear to be abnormally regulated among BCR/ABL + B cell committed leukemic cells.
During B cell differentation, CD10 is one of the earliest antigens to become detectable, 54 ,56 its expression being downregulated as CD34
+ precursors differentiate into mature sIg + /CD20 + B cells. 54 CD10 expression on CD34 + blast cells was found in all BCR/ABL + precursor-B-ALL cases as well as in around half of the BCR/ABL − patients, representing one of the most frequent phenotypes in precursor-B-ALL; these findings suggest that blockade of CD10 down-regulation is a relevant event in leukemic B cell differentiation. In this sense it has been suggested that this surface antigen, which acts as a peptidase, could be involved in arresting normal B cell differentiation through the degradation of peptides which act as B cell differentiation factors. 60 In spite of the singular phenotypic features described above in common for adults with BCR/ABL + precursor B-ALL, there is still a certain degree of heterogenity as regards the expression of several of the surface antigens explored here. This phenotypic heterogenity could be further explained by the DNA ploidy status of leukemic cells. Within BCR/ABL + cases, those with DNA aneuploidy were associated with a higher mean reactivity per cell for the CD10, CD38, CD45 and CD19 antigens. Interestingly, the phenotypic differences on CD10, CD38 and CD45 expression but not CD19, were also noted among the BCR/ABL − diploid vs aneuploid cases (data not shown). These observations would further support the notion that the phenotypic features of leukemic B cells blocked in their maturation at a relatively early differentiation stage to a large extent reflect the underlying genetic aberrations carried by the neoplastic cells.
In summary, the present study shows that adult ALL patients carrying the BCR/ABL + translocation display a unique phenotypic profile (CD34 ++hm /CD10 +hm /CD38
−/lo int /CD13 +int ), the utility of this approach for identifying this subgroup of poor prognosis adult ALL patients deserving further confirmation in larger series of patients in which children with BCR/ABL + ALL are also analyzed.
